Pharmacological treatment of negative symptoms in schizophrenia (Q38431333)

3 September 2017

1 reference

title

Pharmacological treatment of negative symptoms in schizophrenia (English)

1 reference

3 September 2017

1 reference

1

Hans-Jürgen Möller

1 reference

3 September 2017

Pal Czobor

2

1 reference

3 September 2017

21 April 2015

1 reference

European Archives of Psychiatry and Clinical Neuroscience

3 September 2017

1 reference

3 September 2017

265

1 reference

3 September 2017

7

1 reference

3 September 2017

567-578

1 reference

https://scigraph.springernature.com/pub.10.1007/s00406-015-0596-y

3 September 2017

0 references

cites work

Pharmacological approaches to treating negative symptoms: a review of clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

Toward the next generation of negative symptom assessments: the collaboration to advance negative symptom assessment in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

Persistent negative symptoms in schizophrenia: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

A Double-Blind Trial of Amitriptyline/Perphenazine, Perphenazine and Placebo in Chronic Withdrawn Inert Schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

A meta-analysis of the efficacy of second-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

Effects of D-cycloserine on negative symptoms in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

Psychometric evaluation of the negative syndrome of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

Alpha-2 receptor antagonist add-on therapy in the treatment of schizophrenia; a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

Amelioration of negative symptoms in schizophrenia by glycine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

Negative symptoms of schizophrenia are improved by the addition of paroxetine to neuroleptics: a double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

The NIMH-MATRICS consensus statement on negative symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

The brief negative symptom scale: psychometric properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

Meta-analysis of noradrenergic and specific serotonergic antidepressant use in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

The Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

Food and Drug Administration commentary on methodological issues in negative symptom trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

Food and Drug Administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

Neurobiological background for the development of new drugs in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

Methodological issues in negative symptom trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

Clinical evaluation of negative symptoms in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

Management of the negative symptoms of schizophrenia: new treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

Non-neuroleptic approaches to treating negative symptoms in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

The Munich 15-year follow-up study (MUFUSSAD) on first-hospitalized patients with schizophrenic or affective disorders: assessing courses, types and time stability of diagnostic classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

Negative symptoms in schizophrenia: considerations for clinical trials. Working group on negative symptoms in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

Biochemical findings of negative symptoms in schizophrenia and their putative relevance to pharmacologic treatment. A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

Schizophrenia, "just the facts" 5. Treatment and prevention. Past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

D-serine added to antipsychotics for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

D-alanine added to antipsychotics for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

Association between changes on the Negative Symptom Assessment scale (NSA-16) and measures of functional outcome in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

Meta-Analysis of Efficacy of Mirtazapine as an Adjunctive Treatment of Negative Symptoms in Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-015-0596-Y

Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia

21 January 2018

1 reference

12 December 2020

Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials

1 reference

12 December 2020

Glutamatergic drugs for schizophrenia

1 reference

12 December 2020

Clinical update on amisulpride in deficit schizophrenia.

1 reference

12 December 2020

Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials

1 reference

12 December 2020

Adjunctive high-dose glycine in the treatment of schizophrenia

1 reference

12 December 2020

Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients

1 reference

12 December 2020

Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group

1 reference

12 December 2020

Placebo-controlled trial of glycine added to clozapine in schizophrenia

1 reference

12 December 2020

Efficacy of second-generation-antipsychotics in the treatment of negative symptoms of schizophrenia: a meta-analysis of randomized clinical trials

1 reference

12 December 2020

Glutamatergic theories of schizophrenia.

1 reference

12 December 2020

Benefits of trazodone and mianserin for patients with late-life chronic schizophrenia and tardive dyskinesia: an add-on, double-blind, placebo-controlled study.

1 reference

12 December 2020

Treatment of negative symptoms in schizophrenia with amisulpride

1 reference

12 December 2020

Methods for assessing positive and negative symptoms

1 reference

12 December 2020

Improvement of some schizophrenic deficit symptoms with low doses of amisulpride

1 reference

12 December 2020

Antidepressants for the negative symptoms of schizophrenia

1 reference

12 December 2020

Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine

1 reference

12 December 2020

Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study

1 reference

12 December 2020

10.1007/S00406-015-0596-Y

Identifiers

DOI

1 reference

PubMed ID

25895634

Dimensions Publication ID

3 September 2017

0 references

1 reference

PubMed ID

25895634